Sol-Gel Technologies Bolsa (NASDAQ: SLGL)

Sol-Gel Technologies (NASDAQ:SLGL) Bolsa, Quote.MetaTitle.unusual-options

Sol-Gel Technologies

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies Ltd

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Context Therapeutics

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Grace Therapeutics

Hyperion DeFi

ImageneBio

Intercure

Incannex Healthcare

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

Scilex Holding

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Turn Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Sol-Gel Technologies (SLGL) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Interés en corto

Informe de acciones

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Comments

Sol-Gel Technologies Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL